Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Presents Preclinical Data on AAT Deficiency Drug

Premium

Alnylam Pharmaceuticals this week released new preclinical data from its alpha-1 antitrypsin deficiency program, which aims to treat liver disease associated with the rare genetic condition.

According to the company, it has generated data showing that it can achieve “robust RNAi-mediated silencing of AAT liver mRNA and serum protein in a transgenic mouse model of mutant AAT protein over-expression.”

The data were presented at the Annual Meeting of the American Association for the Study of Liver Diseases in Boston this month.

“Approximately 10,000 people worldwide have been diagnosed with severe AAT deficiency, a rare genetic disease that results in severe lung and liver pathology,” Saint Louis University School of Medicine researcher and Alnylam collaborator Jeffrey Teckman said in a statement. “AAT patients can develop early onset emphysema, as well as liver disease, including hepatitis, cirrhosis, and hepatocellular carcinoma. While lung disease associated with AAT deficiency has been addressed with AAT replacement therapy, there are limited treatment options for patients with liver disease.”

Specifically, Alnylam said that AAT-targeting siRNAs formulated in lipid nanoparticles at doses ranging from 0.03 mg/kg to 1 mg/kg could trigger up to a 90 percent knockdown of target mRNA in the liver and a greater than 80 percent decrease in serum AAT in the mice 48 hours after treatment.

“Furthermore, a 90 percent reduction in soluble protein monomers in the liver was observed at 1.0 mg/kg, with an 80 percent reduction seen at 0.3 mg/kg,” Alnylam said.

The company noted that it has identified a GalNAc conjugate-formulated siRNA targeting AAT that enables subcutaneous dose administration for further development.

The Scan

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.

Family Genetic Risk Score Linked to Diagnostic Trajectory in Psychiatric Disorders

Researchers in JAMA Psychiatry find ties between high or low family genetic risk scores and diagnostic stability or change in four major psychiatric disorders over time.

Study Questions Existence of Fetal Microbiome

A study appearing in Nature this week suggests that the reported fetal microbiome might be the result of sample contamination.

Fruit Fly Study Explores Gut Microbiome Effects on Circadian Rhythm

With gut microbiome and gene expression experiments, researchers in PNAS see signs that the microbiome contributes to circadian rhythm synchronicity and stability in fruit flies.